Target Safety Reports: What’s in a Name?

Irrespective of what we call them, target safety reports form a key part of risk assessment and risk mitigation plans in drug discovery and development. Why is that?  Well, target-related toxicity accounts for >50% of all drug project failures (Cook et al., 2014) so it’s vital to understand the potential unintended consequences of target modulation.  [...]

By |2018-10-12T14:15:50+00:00October 12th, 2018|Target Safety Assessments|Comments Off on Target Safety Reports: What’s in a Name?

Understanding drug targets: no such thing as bad news

Abstract: How can small-to-medium pharma and biotech companies enhance the chances of running a successful drug project and maximise the return on a limited number of assets? Having a full appreciation of the safety risks associated with proposed drug targets is a crucial element in understanding the unwanted side-effects that might stop a project in [...]

By |2018-10-01T17:36:10+00:00June 6th, 2018|Target Safety Assessments, Publications|Comments Off on Understanding drug targets: no such thing as bad news

ApconiX Welcomes Dr Jane Barber to The Team

ApconiX is delighted to welcome Dr Jane Barber who joins us from AstraZeneca.  Jane, a dedicated drug discovery research scientist will work with the team of experts in nonclinical safety toxicology at ApconiX. Jane graduated from the University of Keele with a degree in Biology and Classical studies.  After researching Molecular Parasitology and Vector Biology, [...]

By |2018-08-23T10:56:48+00:00May 1st, 2018|Target Safety Assessments, Events|Comments Off on ApconiX Welcomes Dr Jane Barber to The Team

The Value of Target Safety Assessments

Did you know that safety issues remain one of the main reason why drug projects fail?   Multiple publications over recent years have continued to highlight non-clinical safety/toxicity as the most frequent reason for project failure in drug development.  For example, in a study of 605 projects from GSK, AstraZeneca, Ely Lilly and Pfizer, nonclinical toxicology [...]

By |2018-07-11T11:02:07+00:00February 28th, 2018|Target Safety Assessments|Comments Off on The Value of Target Safety Assessments

Target safety assessments and their role in de-risking drug discovery – Nav1.7 as an example

  This poster, presented at the Gordon Research Conference in August 2017, concluded that: Target safety assessments: Provide expert assessment and interpretation of literature and available databases and are invaluable in identifying and avoiding target-related risks Inform target selection and/or prioritisation early in discovery Should contain the level of detail appropriate to the project stage Should [...]

By |2018-10-10T09:38:24+00:00August 20th, 2017|Target Safety Assessments, Publications|Comments Off on Target safety assessments and their role in de-risking drug discovery – Nav1.7 as an example

Target Safety Assessments: Strategies and Resources

Target Safety Assessment: Strategies and Resources, Chapter 12 of Drug Safety Evaluation Methods in Molecular Biology (vol 1641), was written by Dr Richard J Brennan, a Scientific Advisor at Sanofi in the United States. The chapter presents a summary of the information types and sources that should be investigated, and approaches that can be taken [...]

By |2018-10-10T09:31:45+00:00July 27th, 2017|Target Safety Assessments, Publications|Comments Off on Target Safety Assessments: Strategies and Resources